Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer

[1]  W. Oyen,et al.  Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Drew A. Torigian,et al.  Repeatability of 18F-FDG PET/CT in Advanced Non–Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials , 2015, The Journal of Nuclear Medicine.

[3]  H. McArthur,et al.  FDG-PET/CT versus contrast enhanced CT for prediction of progression-free and disease-specific survival in stage IV breast cancer patients. , 2015 .

[4]  D. Groheux,et al.  Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  G. Cook,et al.  Imaging breast cancer bone metastases: current status and future directions. , 2013, Seminars in nuclear medicine.

[6]  M. Piccart,et al.  Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  V. Edeline,et al.  Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  G. Hortobagyi,et al.  FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. , 2011, The oncologist.

[9]  S. Larson,et al.  Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[11]  Jeanne Kowalski,et al.  Assessment of Interobserver Reproducibility in Quantitative 18F-FDG PET and CT Measurements of Tumor Response to Therapy , 2009, Journal of Nuclear Medicine.

[12]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[13]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Ukihide Tateishi,et al.  Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. , 2008, Radiology.

[15]  D. Mankoff,et al.  Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP) , 2007, Breast Cancer Research and Treatment.

[16]  Ludovic Ferrer,et al.  Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[18]  M. Gonen,et al.  Concordance probability and discriminatory power in proportional hazards regression , 2005 .

[19]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[20]  D. Mankoff,et al.  Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. , 2002, Academic radiology.

[21]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[23]  E. Karabulut,et al.  Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan? , 2016, Revista espanola de medicina nuclear e imagen molecular.

[24]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[26]  望月由貴人,et al.  全身18F‐fluorodeoxyglucose(FDG)positron emission tomography(PET)検査で偶発的に認められた尿路集積異常 , 2000 .

[27]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.